|
1.
|
Pharmacology of catamenial epilepsy
|
Reddy
|
2004
|
|
2.
|
Role of neurosteroids in catamenial epilepsy
|
Reddy
|
2004
|
|
3.
|
Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice
|
Kaminski, et al.
|
2004
|
|
4.
|
Pharmacology of endogenous neuroactive steroids
|
Reddy
|
2003
|
|
5.
|
Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice
|
Kaminski, et al.
|
2003
|
|
6.
|
Catamenial epilepsy: pathophysiology, diagnosis, and management
|
Foldvary-Schaefer, et al.
|
2003
|
|
7.
|
Conversion to monotherapy: clinical trials in patients with refractory partial seizures
|
Beydoun, et al.
|
2003
|
|
8.
|
The contraceptive agent Provera enhances GABA(A) receptor-mediated inhibitory neurotransmission in the rat hippocampus: evidence for endogenous neurosteroids?
|
Belelli, et al.
|
2003
|
|
9.
|
Neurosteroids and infantile spasms: the deoxycorticosterone hypothesis
|
Rogawski, et al.
|
2002
|
|
10.
|
Newer GABAergic agents for pharmacotherapy of infantile spasms
|
Reddy
|
2002
|
|
11.
|
Changes in GABA(A) receptor gene expression induced by withdrawal of, but not by long-term exposure to, ganaxolone in cultured rat cerebellar granule cells
|
Mascia, et al.
|
2002
|
|
12.
|
Acute treatments: some blind alleys
|
Ramadan
|
2001
|
|
13.
|
A high-performance liquid chromatography-tandem mass spectrometric method for the determination of pharmacokinetics of ganaxolone in rat, monkey, dog and human plasma
|
Ram, et al.
|
2001
|
|
14.
|
Future prospects for the drug treatment of epilepsy
|
Nicolson, et al.
|
2001
|
|
15.
|
Early postnatal ethanol intubation blunts GABA(A) receptor up-regulation and modifies 3alpha-hydroxy-5alpha-pregnan-20-one sensitivity in rat MS/DB neurons
|
Hsiao, et al.
|
2001
|
|
16.
|
The new generation of GABA enhancers. Potential in the treatment of epilepsy
|
Czuczwar, et al.
|
2001
|
|
17.
|
Clinical pharmacology of new antiepileptic drugs
|
Willmore
|
2000
|
|
18.
|
Neuroactive steroids attenuate cocaine-induced sucrose intake in rats, but not cocaine-induced hyperactivity in mice
|
Vanover, et al.
|
2000
|
|
19.
|
Modification of behavioral effects of drugs in mice by neuroactive steroids
|
Ungard, et al.
|
2000
|
|
20.
|
Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy
|
Reddy, et al.
|
2000
|
|
21.
|
Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself
|
Reddy, et al.
|
2000
|
|
22.
|
Effect of ganaxolone in a rodent model of cerebral hematoma
|
Lyden, et al.
|
2000
|
|
23.
|
Effect of ganaxolone on flurothyl seizures in developing rats
|
Liptakova, et al.
|
2000
|
|
24.
|
Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group
|
Laxer, et al.
|
2000
|
|
25.
|
Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial
|
Kerrigan, et al.
|
2000
|
|
26.
|
An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development
|
Jain
|
2000
|
|
27.
|
Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: comparison with diazepam and valproate
|
Gasior, et al.
|
2000
|
|
28.
|
New anti-epileptic drugs
|
Walker, et al.
|
1999
|
|
29.
|
Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures
|
Schachter, et al.
|
1999
|
|
30.
|
Ganaxolone: a novel positive allosteric modulator of the GABA(A) receptor complex for the treatment of epilepsy
|
Monaghan, et al.
|
1999
|
|
31.
|
Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV)
|
Bialer, et al.
|
1999
|
|
32.
|
Ganaxolone, a selective, high-affinity steroid modulator of the gamma-aminobutyric acid-A receptor, exacerbates seizures in animal models of absence
|
Snead
|
1998
|
|
33.
|
Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxolone
|
Beekman, et al.
|
1998
|
|
34.
|
Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity
|
Monaghan, et al.
|
1997
|
|
35.
|
Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam
|
Gasior, et al.
|
1997
|
|
36.
|
Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor
|
Carter, et al.
|
1997
|
|
37.
|
Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. The US Gabapentin Study Group 88/89
|
Bergey, et al.
|
1997
|
|
38.
|
Epalons as anticonvulsants: actions mediated by the GABAA receptor complex
|
Gee
|
1996
|
|
39.
|
Felbamate monotherapy: implications for antiepileptic drug development
|
Theodore, et al.
|
1995
|
|
40.
|
Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures
|
Devinsky, et al.
|
1995
|
|
41.
|
Neurosteroids: a new brain function?
|
Baulieu, et al.
|
1990
|
Indications